Equity Overview
Price & Market Data
Price: $5.50
Daily Change: -$0.18 / 3.27%
Range: $5.36 - $5.69
Market Cap: $58,025,552
Volume: 83,831
Performance Metrics
1 Week: 9.78%
1 Month: 8.06%
3 Months: 10.00%
6 Months: -37.64%
1 Year: -43.18%
YTD: 44.36%
Company Details
Employees: 108
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. It offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. The company also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.